Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target
Benzinga Newsdesk 3 months ago
NewsDowngradesAnalyst RatingsPrice Target
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.